Comparable stake leader
James Alexander Cunliffe Foster
SEC ownership of Virax Biolabs Group Ltd
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001885827.
Disclosed value leader
James Alexander Cunliffe Foster
Comparable rows
2/2
Latest evidence
31 Mar 2026
- Public ticker
- VRAX on Nasdaq
- Parsed ownership sources
-
13D/G and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
James Alexander Cunliffe Foster
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
2 of 2
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
James Alexander Cunliffe Foster
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
31 Mar 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001885827
- Issuer location
- Lanarkshire, United Kingdom
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Virax Biolabs Group Ltd (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
James Alexander Cunliffe ...
Disclosed value leader
James Alexander Cunliffe ...
Comparable rows
2/2
Latest evidence
31 Mar 2026
13D/G
3/4/5
Lead comparable stake: 8.3%
13D/G row: James Alexander Cunliffe Foster
Quick read
James Alexander Cunliffe Foster leads the comparable SEC ownership view at 8.3%.
2 of 2 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens James Alexander Cunliffe Foster's linked filing trail.
Comparable ownership
Top 2
James Alexander Cunliffe Foster
8.3%
ARMISTICE CAPITAL, LLC
5%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-2 of 2 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| James Alexander Cunliffe Foster |
13D/G
3/4/5
James Foster · Chief Executive Officer
|
8.3%
Reported 13D/G
· 31 Mar 2025
|
$232,199
368,570 shares
|
+$30,634 | 31 Mar 2025 |
| ARMISTICE CAPITAL, LLC |
13D/G
|
5%
Reported 13D/G
· 31 Mar 2026
|
$170,041
1,000,239 shares
|
+$29,976 | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
No eligible buy or sell activity is available for this window. No eligible Buy or Sell transactions are available in this dataset since 15 Nov 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-7 of 7 reporting-owner rows connected to Virax Biolabs Group Ltd. Open a relationship link for the CIK-to-CIK filing trail.
Rows
7
Largest Forms 3/4/5 holder
James Alexander Cunliffe Foster
Net 12M change
$0
Latest report
05 Oct 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| James Alexander Cunliffe Foster | Chief Executive Officer | $63,357 | Mixed | 18 Mar 2026 | ||
| Jason Davis | Chief Financial Officer | Mixed | 18 Mar 2026 | |||
| Evan Michael Norton | Director | Mixed | 18 Mar 2026 | |||
| Iain David Miller | Director | Mixed | 18 Mar 2026 | |||
| Nigel William McCracken | Chief Operating Officer, Director | Mixed | 18 Mar 2026 | |||
| Nelson M. Haight | Director | Mixed | 18 Mar 2026 | |||
| Clement Monteil | Chief Scientific Officer | Mixed | 05 Oct 2026 |
Recent insider transactions for Virax Biolabs Group Ltd
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| James Alexander Cunliffe Foster | VRAX | Ordinary Shares | 0 | 287,987 | 18 Mar 2026 | Direct |
* marks a reported price that did not pass the local price check.